1991
Bristol Myers Squibb's Peter Lindsley's group filed on CTLA-4 in June 1991, about three years before Jim Allison's lab worked out what it did.
“Pierre Lindsley's group at BMS got there in June of 1991, three years ahead of Allison.”
Topic
8 facts from 6 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
1991
Bristol Myers Squibb's Peter Lindsley's group filed on CTLA-4 in June 1991, about three years before Jim Allison's lab worked out what it did.
“Pierre Lindsley's group at BMS got there in June of 1991, three years ahead of Allison.”
2012
On February 15, 2012, Bristol-Myers Squibb CEO Lamberto Andreotti offered $22 a share for Amylin, which the board rejected without disclosing it.
“He's calling with an offer to Amylin, $22 a share to buy the whole company. At the time, Amylin is trading around $14 to $16 a share.”
2012
In BMS's early nivolumab data, none of 17 PD-L1-negative patients responded, while nine of 25 PD-L1-positive patients did.
“Out of 42 patients they evaluated, zero of the 17 PD-L1 negative patients responded, but nine out of the 25 PD-L1 positive patients did.”
2021
Scott Cleve said bluebird bio had a PDUFA date that week for its multiple myeloma product, co-developed with BMS.
“this week, we have a PDUFA date coming up for our multiple myeloma product that we're co-developing with BMS.”
Undated
Nick Hellman was recruited to Bristol-Myers Squibb to work on an early antiretroviral drug, which took the couple to Connecticut.
“And then Nick got recruited to Bristol-Myers Squibb to work on D14, one of the first antiretroviral drugs.”
Undated
Kevin Mahoney says Penn can search its shared electronic medical record to find patients for pharmaceutical clinical trials, such as one for Bristol Myers Squibb.
“you can mine through the EMR to find the patients that you need for that Crystal Myers clinical trial.”
Undated
BMS's all-comers first-line lung cancer trial Checkmate 26 had a hazard ratio of 1.02 and failed, while Merck's enriched Keynote 24 trial succeeded.
“BMS's all comers trial, Checkmate 26, produced a hazard ratio of 1.02. It showed absolutely zero benefit and completely failed.”
Undated
Bristol Myers Squibb chose to pursue the first ALS target as a small molecule, while Insitro advances it as an intrathecal oligonucleotide at its own cost.
“BMS elected to pursue the first of those targets, ALS-1, as a small molecule.”
Episodes